Cost‐effectiveness of second‐line empagliflozin versus liraglutide for type 2 diabetes in the United States.
- Published in:
- Diabetes, Obesity & Metabolism, 2022, v. 24, n. 4, p. 652, doi. 10.1111/dom.14625
- By:
- Publication type:
- Article
Works matching AU SHETTY, SHARASH
Results: 15
1
2
Cost‐effectiveness analysis of empagliflozin versus sitagliptin as second‐line therapy for treatment in patients with type 2 diabetes in the United States.
- Published in:
- Diabetes, Obesity & Metabolism, 2021, v. 23, n. 3, p. 791, doi. 10.1111/dom.14268
- By:
- Publication type:
- Article
3
Impact of timing of nintedanib initiation among patients newly diagnosed with idiopathic pulmonary fibrosis.
- Published in:
- Journal of Medical Economics, 2022, v. 25, n. 1, p. 532, doi. 10.1080/13696998.2022.2054203
- By:
- Publication type:
- Article
4
Impact of chronic fibrosing interstitial lung disease on healthcare use: association between fvc decline and inpatient hospitalization.
- Published in:
- BMC Pulmonary Medicine, 2023, v. 23, n. 1, p. 1, doi. 10.1186/s12890-023-02637-8
- By:
- Publication type:
- Article
5
Healthcare Costs and Resource Utilization Associated with the Use of Empagliflozin Versus Other Antihyperglycemic Agents Among Patients with Type 2 Diabetes Mellitus and Cardiovascular Disease: A Real-World Retrospective Cohort Analysis.
- Published in:
- Diabetes Therapy, 2022, v. 13, n. 1, p. 25, doi. 10.1007/s13300-021-01173-0
- By:
- Publication type:
- Article
6
The cost of cardiovascular-disease-related death in patients with type 2 diabetes mellitus.
- Published in:
- 2018
- By:
- Publication type:
- journal article
7
Incremental burden of type 2 diabetes in patients experiencing cardiovascular hospitalizations.
- Published in:
- 2018
- By:
- Publication type:
- journal article
8
Concordance with prescribing information dosage recommendations for dipeptidyl-peptidase-4 inhibitors among type 2 diabetes mellitus patients with moderate to severe chronic kidney disease.
- Published in:
- 2018
- By:
- Publication type:
- journal article
9
808-P: Economic Benefits of Initiating Empagliflozin vs. GLP-1 Receptor Agonists among Patients with Type 2 Diabetes.
- Published in:
- Diabetes, 2021, v. 70, p. N.PAG, doi. 10.2337/db21-808-P
- By:
- Publication type:
- Article
10
1158-P: Cost-Effectiveness of Empagliflozin vs. Liraglutide as Second-Line Therapy for Type 2 Diabetes in the United States.
- Published in:
- Diabetes, 2020, v. 69, p. N.PAG, doi. 10.2337/db20-1158-P
- By:
- Publication type:
- Article
11
1152-P: Effect of Initiating Empagliflozin vs. Glucagon-Like Peptide-1 Receptor Agonists on Health-Care Costs among Patients with Type 2 Diabetes.
- Published in:
- Diabetes, 2020, v. 69, p. N.PAG, doi. 10.2337/db20-1152-P
- By:
- Publication type:
- Article
12
2234-PUB: A Risk Prediction Model for End-Stage Renal Disease in Patients with Type 2 Diabetes Mellitus.
- Published in:
- Diabetes, 2019, v. 68, p. N.PAG, doi. 10.2337/db19-2234-PUB
- By:
- Publication type:
- Article
13
A risk prediction model for heart failure hospitalization in type 2 diabetes mellitus.
- Published in:
- Clinical Cardiology, 2020, v. 43, n. 3, p. 275, doi. 10.1002/clc.23298
- By:
- Publication type:
- Article
14
Claims-based Prevalence of Disease Progression among Patients with Fibrosing Interstitial Lung Disease Other than Idiopathic Pulmonary Fibrosis in the United States.
- Published in:
- 2022
- By:
- Publication type:
- journal article
15
Adoption of Antifibrotic Medications: A Closer Look at the Data.
- Published in:
- 2021
- By:
- Publication type:
- Letter